Computed Tomographic Angiography of the Pancreas in Cats with Chronic Diabetes Mellitus Compared to Normal Cats.

BACKGROUND: Diabetes mellitus (DM) is a common endocrinopathy in cats. No known diagnostic test or patient characteristic at the time of diagnosis can predict likely disease course, unlike in people in whom computed tomographic angiography (CTA) is used. No published data exist regarding the CTA appearance of the pancreas in cats with DM, and thus, it is unknown what if any CTA variables should be further assessed for associations with pancreatic endocrine function. HYPOTHESIS/OBJECTIVES: A significant difference in pancreatic attenuation, volume, and size will be identified between normal cats and those with chronic DM on CTA. ANIMALS: Ten healthy control cats and 15 cats with naturally occurring DM present for >12 months. METHODS: Prospective cross-sectional study comparing pancreatic attenuation, enhancement pattern, size, volume, pancreatic volume-to-body weight ratio (V:BW), pancreatic arterial: portal phase ratio (A:P), time-to-arterial enhancement, and time-to-peak portal enhancement on CTA between sedated healthy control cats and those with chronic DM. RESULTS: The pancreas in cats with chronic DM was significantly larger, had higher volume, higher V:BW, and shorter time-to-peak portal enhancement on CTA when compared to normal cats. CONCLUSIONS AND CLINICAL IMPORTANCE: Peak portal enhancement time, pancreatic size, pancreatic volume, and V:BW can be used to differentiate normal sedated cats from those with chronic DM by CTA. These variables warrant further investigation to identify possible associations with endocrine function.

Computed tomographic excretory urography features of intramural ectopic ureters in 10 dogs.

OBJECTIVES: To describe the morphologic and morphometric computed tomographic excretory urography features of intramural ectopic ureters in dogs. METHODS: Retrospective evaluation of computed tomographic excretory urography studies in 10 dogs with surgical and/or cystoscopically confirmed intramural ectopic ureters. All studies were assessed for ureteral ectopia, dilatation, tortuosity, ureterovesicular junction morphology and ureteral orifice location. RESULTS: A total of 14 intramural ectopic ureters were confirmed at surgery/cystoscopy with reviewers correctly identifying 100% (14/14). Abnormalities on computed tomographic excretory urography included ureteral dilatation (7), ureteral tortuosity (3), lack of a normal ureterovesicular junction (14), urethral ureteral orifice location (14) and lack of ureteral divergence (14). CLINICAL SIGNIFICANCE: Lack of a normal ureterovesicular junction, a urethral-ureteral orifice location and lack of ureteral divergence are common computed tomographic excretory urography findings in dogs with intramural ectopic ureters. This technique requires further investigation to determine whether it might allow differentiation of intramural and extramural ectopic ureters.

High-level semi-synthetic production of the potent antimalarial artemisinin.

In 2010 there were more than 200 million cases of malaria, and at least 655,000 deaths. The World Health Organization has recommended artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria caused by the parasite Plasmodium falciparum. Artemisinin is a sesquiterpene endoperoxide with potent antimalarial properties, produced by the plant Artemisia annua. However, the supply of plant-derived artemisinin is unstable, resulting in shortages and price fluctuations, complicating production planning by ACT manufacturers. A stable source of affordable artemisinin is required. Here we use synthetic biology to develop strains of Saccharomyces cerevisiae (baker's yeast) for high-yielding biological production of artemisinic acid, a precursor of artemisinin. Previous attempts to produce commercially relevant concentrations of artemisinic acid were unsuccessful, allowing production of only 1.6 grams per litre of artemisinic acid. Here we demonstrate the complete biosynthetic pathway, including the discovery of a plant dehydrogenase and a second cytochrome that provide an efficient biosynthetic route to artemisinic acid, with fermentation titres of 25 grams per litre of artemisinic acid. Furthermore, we have developed a practical, efficient and scalable chemical process for the conversion of artemisinic acid to artemisinin using a chemical source of singlet oxygen, thus avoiding the need for specialized photochemical equipment. The strains and processes described here form the basis of a viable industrial process for the production of semi-synthetic artemisinin to stabilize the supply of artemisinin for derivatization into active pharmaceutical ingredients (for example, artesunate) for incorporation into ACTs. Because all intellectual property rights have been provided free of charge, this technology has the potential to increase provision of first-line antimalarial treatments to the developing world at a reduced average annual price.

Effects of processing milk on concentrations of glucocorticoids in milk.

Concentrations of glucocorticoids were measured by protein binding in milk subjected to various processing methods. Raw whole milk was collected once per week for 3 wk from bulk milk tanks of each of 10 farms. Nine combinations of processing were tested: 1) none, 2) high-temperature short-time pasteurization of whole milk, 3) high-temperature short-time pasteurization and homogenization of whole milk, 4) bulk pasteurization of whole milk, 5) bulk pasteurization and homogenization of whole milk, 6) high-temperature short-time pasteurization of skim milk, 7) high-temperature short-time pasteurization and homogenization of skim milk, 8) bulk pasteurization of skim milk, and 9) bulk pasteurization and homogenization of skim milk. Mean concentrations of total glucocorticoids ranged from .46 to .65 ng/ml and were not different among either processing methods or whole versus skim milk classifications. No correlations were positive between percentage of fat and concentration of glucocorticoids in whole milk (-.22) or skim milk(-.09).